Answers are grounded in this paper and cite their sources.
In this work, we demonstrate for the first time the antimicrobial activity of poly-Q binding peptide 1 (QBP1), an anti-amyloidogenic molecule previously identified by phage display for its ability to bind and inhibit the aggregation of polyglutamine proteins like Huntingtin, but also α-synuclein and prion models. Intriguingly, sequence analysis by the ADAPTABLE web server highlighted QBP1's potential antifungal and antibacterial activity, which we have now confirmed experimentally. A theoretical basis for the predicted mechanism of action was provided by molecular dynamics simulations revealing the role of QBP1 aggregates promoting membrane disruption and specific interactions between QBP1 and bacterial and fungal phospholipids, further substantiated by solid-state NMR studies. Using primary human cells, we demonstrated that QBP1 does not display toxicity at high concentrations. Finally, our data demonstrate QBP1's efficacy against some strains of Bacillus cereus, B. mojavensis, Staphylococcus aureus, S. epidermidis, Micrococcus luteus, Enterococcus faecalis, Escherichia coli, and Candida. This unexpected dual function of QBP1 opens new avenues for therapeutic development, potentially restoring the putative antimicrobial protection exerted by many amyloidogenic proteins. QBP1, an anti-amyloidogenic peptide, has been predicted to possess antimicrobial activity. Originally identified for its ability to inhibit protein aggregation, QBP1 can disrupt bacterial and fungal membranes through aggregation and direct lipid interactions. This dual anti-amyloidogenic and antimicrobial function offers exciting possibilities for synergic action, particularly in addressing intracerebral antimicrobial infections and neurodegeneration. • We report the first evidence of antimicrobial activity for anti-amyloid peptide QBP1. • We confirmed inhibition of fungi and bacteria, including S. aureus and E. coli. • Molecular dynamics reveals how QBP1 disrupts bacterial and fungal membranes. • Solid-state NMR studies highlighted selective phospholipids targeting in-vitro. • Dual function of QBP1 sparks potential therapeutic innovations.
No takes yet. Share an insight, caveat, or question.
Ramos‐Martín et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: